Acacia Pharma is a specialty pharmaceutical company focused on the development and commercialisation of new treatments for supportive care of patients with debilitating conditions arising as a consequence of surgery, cancer or cancer treatment.
Acacia has generated a pipeline of product opportunities addressing a range of cancer supportive care indications, such as nausea and vomiting, xerostomia and cachexia, using a commercially driven approach to product development by identifying new uses for already marketed drugs. The pipeline has been generated by repurposing drugs already marketed for other uses that have biological properties appropriate for their development as patented products for supportive care.
Acacia ’s management team has extensive experience in drug repurposing and the development and commercialisation of specialty and supportive care pharmaceutical products. Founded in 2007 and based in Cambridge, it also has US operations in Indianapolis.